Evidence map›Paper›PMID 38932878›Full record

ArticleJournal of diabetes and metabolic disorders2024

Nafiseh Zare, Fatemeh Bandarian, Ensieh Nasli Esfahani, Bagher Larijani, Mohammad Mahdavi, Maryam Mohammadi-Khanaposhtani, Hossein Najafzadehvarzi

Abstract read
In one paragraph

Article in Journal of diabetes and metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Journal of diabetes and metabolic disorders · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nafiseh ZareFaculty of Pharmacy, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran.
Fatemeh BandarianDiabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, University of Medical Sciences, Tehran, Iran.
Ensieh Nasli EsfahaniDiabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, University of Medical Sciences, Tehran, Iran.
Bagher LarijaniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad MahdaviEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Maryam Mohammadi-KhanaposhtaniCellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.ORCID 0000-0001-7664-9664
Hossein NajafzadehvarziCellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Methods: The Results: The results obtained indicated a significant reduction in blood glucose levels with Conclusion: In summary, the study demonstrated the

Indexed as

DiabetesPyrano[3,2-c]quinolineStreptozotocinSyntheticWistar rat

Identifiers

PMID38932878
PMCPMC11196494

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.